Distinguished in Neuroendocrine Tumor

Isabel A. Sevilla

Malaga, AN, ES 
Distinguished in Neuroendocrine Tumor
Malaga, AN, ES 
OverviewLocationsClinical Research

Overview

Isabel Sevilla practices in Malaga, Spain. Ms. Sevilla is rated as a Distinguished expert by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Pancreatic Islet Cell Tumor, Neuroendocrine Tumor, Embryonal Tumor with Multilayered Rosettes, and Colorectal Cancer.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 20 articles and participated in 2 clinical trials in the study of Neuroendocrine Tumor.

Gender
Female

Locations

Malaga, AN, Spain
Other Locations
Sevilla, AN, Spain
Madrid, MD 28040, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
Enrollment Status: Unknown
Publish Date: March 16, 2022
Intervention Type: Biological, Drug
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Unknown
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

41 Total Publications

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sevilla's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile